Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir Prophylaxis Duration Based on CMV Immunity in HCT Recipients
NCT06639854Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Proportion of Clinically Significant Cytomegalovirus Infection and Safety and Adverse Events. Started Nov 2024; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06639854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639854.